

# Natalia Buza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2398388/publications.pdf>

Version: 2024-02-01

100  
papers

3,205  
citations

159585

30  
h-index

182427

51  
g-index

103  
all docs

103  
docs citations

103  
times ranked

3471  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. <i>Journal of Clinical Oncology</i> , 2018, 36, 2044-2051.	1.6	313
2	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelialâ€“mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	7.1	181
3	Randomized Phase II Trial of Carboplatinâ€“Paclitaxel Compared with Carboplatinâ€“Paclitaxelâ€“Trastuzumab in Advanced (Stage IIIâ€“IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 3928-3935.	7.0	154
4	Regression of Chemotherapy-Resistant Polymerase Îµ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. <i>Clinical Cancer Research</i> , 2016, 22, 5682-5687.	7.0	145
5	Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. <i>Modern Pathology</i> , 2013, 26, 1605-1612.	5.5	125
6	HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 343-350.	2.5	120
7	Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). <i>Gynecologic Oncology</i> , 2020, 157, 161-166.	1.4	106
8	Hydatidiform Moles: Genetic Basis and Precision Diagnosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 449-485.	22.4	91
9	Mismatch repair deficiency testing in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 591-604.	3.1	66
10	Marked heterogeneity of <i>HER2/NEU</i> gene amplification in endometrial serous carcinoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1178-1186.	2.8	56
11	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibodyâ€“Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1900-1909.	4.1	55
12	HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. <i>Modern Pathology</i> , 2020, 33, 118-127.	5.5	53
13	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
14	T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 29-38.	3.3	51
15	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibodyâ€“Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5836-5845.	7.0	51
16	Partial Hydatidiform Mole. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 307-315.	1.4	50
17	HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 687-691.	2.5	50
18	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	7.1	49

#	ARTICLE	IF	CITATIONS
19	Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	48
20	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research, 2018, 24, 3282-3291.	7.0	44
21	Tubulin $\beta$ overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer, 2013, 119, 2582-2592.	4.1	43
22	Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology, 2020, 159, 17-22.	1.4	42
23	Class III $\beta$ -tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical and Experimental Metastasis, 2014, 31, 101-110.	3.3	40
24	Intravenous Leiomyomatosis Revisited. International Journal of Gynecological Pathology, 2015, 34, 169-176.	1.4	40
25	Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium. Modern Pathology, 2014, 27, 675-680.	5.5	39
26	Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. Human Pathology, 2014, 45, 1885-1892.	2.0	39
27	Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases. Seminars in Diagnostic Pathology, 2014, 31, 223-232.	1.5	38
28	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology, 2017, 146, 179-186.	1.4	37
29	Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Modern Pathology, 2019, 32, 650-658.	5.5	37
30	Inverse p16 and p63 Expression in Small Cell Carcinoma and High-Grade Urothelial Cell Carcinoma of the Urinary Bladder. International Journal of Surgical Pathology, 2010, 18, 94-102.	0.8	36
31	Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 337-345.	2.8	32
32	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget, 2020, 11, 560-570.	1.8	32
33	FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors: Genotype-Phenotype Correlation With Diagnostic Considerations. International Journal of Gynecological Pathology, 2018, 37, 305-315.	1.4	31
34	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports, 2020, 10, 973.	3.3	31
35	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers in Oncology, 2020, 10, 118.	2.8	30
36	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer, 2022, 128, 1206-1218.	4.1	28

#	ARTICLE	IF	CITATIONS
37	Comparative Analysis of P16 and P53 Expression in Uterine Malignant Mixed Mullerian Tumors. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 514-521.	1.4	27
38	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. <i>British Journal of Cancer</i> , 2016, 115, 303-311.	6.4	27
39	Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 47-64.	2.5	27
40	Class III $\beta$ -tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 62.e1-62.e9.	1.3	26
41	<i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011.	4.1	25
42	HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 17-23.	1.4	25
43	Gestational trophoblastic disease: histopathological diagnosis in the molecular era. <i>Diagnostic Histopathology</i> , 2010, 16, 526-537.	0.4	24
44	Endometrial Carcinoma With Trophoblastic Components: Clinicopathologic Analysis of a Rare Entity. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 174-190.	1.4	24
45	Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. <i>Modern Pathology</i> , 2021, 34, 1194-1202.	5.5	24
46	Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability. <i>Human Pathology</i> , 2014, 45, 549-555.	2.0	23
47	Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients. <i>Modern Pathology</i> , 2020, 33, 1172-1181.	5.5	23
48	Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis. <i>Modern Pathology</i> , 2017, 30, 1467-1475.	5.5	22
49	Immunohistochemistry in Gynecologic Pathology: An Example-Based Practical Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1052-1071.	2.5	20
50	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	4.6	20
51	Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. <i>Modern Pathology</i> , 2020, 33, 1979-1988.	5.5	20
52	Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor Encephalitis. <i>American Journal of Surgical Pathology</i> , 2019, 43, 949-964.	3.7	19
53	Egg Donor Pregnancy. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 507-510.	1.4	18
54	Mitotically Active Microglandular Hyperplasia of the Cervix. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 524-530.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model. <i>Scientific Reports</i> , 2017, 7, 40989.	3.3	18
56	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	1.4	18
57	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	7.0	18
58	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	1.4	18
59	Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women. <i>Modern Pathology</i> , 2019, 32, 1271-1280.	5.5	17
60	Genital tuberculosis screening at an academic fertility center in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 737.e1-737.e10.	1.3	17
61	Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine. <i>Modern Pathology</i> , 2021, 34, 1658-1672.	5.5	17
62	Molecular and clinicopathologic characterization of intravenous leiomyomatosis. <i>Modern Pathology</i> , 2020, 33, 1844-1860.	5.5	16
63	Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 263-271.	1.4	16
64	Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. <i>Modern Pathology</i> , 2019, 32, 1180-1188.	5.5	15
65	Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad Ligament. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 58-63.	1.4	14
66	Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). <i>Gynecologic Oncology Reports</i> , 2017, 19, 10-12.	0.6	14
67	Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. <i>Breast Journal</i> , 2018, 24, 976-980.	1.0	14
68	Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study. <i>Histopathology</i> , 2016, 69, 383-392.	2.9	13
69	Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 101-106.	1.4	12
70	An unexpected mass of the urachus: a case report. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, e1-e3.	1.3	11
71	Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. <i>Human Pathology</i> , 2015, 46, 1000-1005.	2.0	11
72	HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 132-141.	1.4	11

#	ARTICLE	IF	CITATIONS
73	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. <i>Gynecologic Oncology</i> , 2021, 163, 334-341.	1.4	10
74	Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 58-77.	1.5	10
75	Intraoperative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes. <i>Histopathology</i> , 2018, 73, 109-123.	2.9	9
76	KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. <i>Modern Pathology</i> , 2018, 31, 350-357.	5.5	7
77	Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. <i>Human Pathology</i> , 2021, 118, 1-8.	2.0	6
78	Grading of atypia in genital skin lesions: routine microscopic evaluation and use of p16 immunostaining. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 519-526.	1.3	5
79	A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus <i>MLH</i>-1 methylated characteristics (NCT02899793).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5523-5523.	1.6	5
80	Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703.	6.4	5
81	Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2018, 23, 28-33.	0.6	4
82	Lack of genetic homozygosity in prepubertal teratomas: divergent pathogenesis distinct from that of teratomas in adolescents. <i>Laboratory Investigation</i> , 2020, 100, 1447-1454.	3.7	4
83	Characteristics of <i>HER2</i> Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma: Implications for Clinical HER2 Testing and Interpretation. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 331-337.	2.5	4
84	Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	3
85	Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100554.	0.6	3
86	Ovarian Sertoli Leydig cell tumors: a single institution series of predominantly postmenopausal women.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17052-e17052.	1.6	2
87	Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100913.	0.6	2
88	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14009-e14009.	1.6	1
89	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17028-e17028.	1.6	1
90	Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6084-6084.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Urinary hCG Screening in the Gynecologic Oncology Population. Journal of Gynecologic Surgery, 2011, 27, 143-146.	0.1	0
92	Ancillary Techniques to Refine Diagnosis of GTD. Current Obstetrics and Gynecology Reports, 2014, 3, 65-75.	0.8	0
93	Putative Precursor Lesions of Gestational Trophoblastic Neoplasia. , 2016, , 85-102.		0
94	Intraoperative Consultation. , 2021, , 317-343.		0
95	Gestational Trophoblastic Diseases. , 2021, , 173-191.		0
96	Immunohistochemistry. , 2021, , 367-416.		0
97	HER2 as Biomarker for Endometrial Cancer. , 2014, , 1-16.		0
98	Intrauterine Pregnancy and Gestational Trophoblastic Disease. , 2015, , 141-149.		0
99	HER2 as Biomarker for Endometrial Cancer Epidermal growth factor receptor-2 HER2. Biomarkers in Disease, 2015, , 507-526.	0.1	0
100	Ancillary studies for precision diagnosis of hydatidiform moles. Diagnostic Histopathology, 2017, 23, 292-302.	0.4	0